Esophageal adenocarcinoma phenotypes and risk factors
Authors:
- 1 July 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 38 (4) , 423-427
Abstract
Purpose of review: The incidence of esophageal adenocarcinoma (EAC) has increased significantly over the last several decades. The majority of EAC patients present without a prior history of Barrett's esophagus (BE). As a result, endoscopic surveillance has made a suboptimal impact on EAC survival. These concerns raise serious question whether the time has come to take a different direction. The aim of this article is to review evolving evidence of EAC phenotypes and risk factors. Recent findings: A recent study has identified two phenotypes of EAC based on the presence or absence of intestinal metaplasia (IM) in the background of the tumor (BE/IM and non-BE/IM). The study found that one-half of patients with EAC have the non-BE/IM phenotype, which is associated with more aggressive behavior and worse survival. A retrospective review demonstrates that the proportion of the two phenotypes has been stable over the last decades. Similarly, the increasing incidence of EAC cannot be explained by an increased frequency of new, unique risk factors but rather by a higher prevalence of already known risk factors. Emerging data also demonstrates that, whereas reflux symptoms are an unreliable feature for screening regardless of phenotype, the absence of reflux symptoms is more common for the non-BE/IM. Differences in the degree of genomic methylation and immune response might explain the two phenotypes at a genomic level. Summary: EAC phenotypes have implications for tumor behavior and phenotypic differences might underlie our suboptimal screening efforts. Future screening efforts should not uniformly rely on reflux symptoms as a prerequisite for screening and should consider alternatives to the current screening strategy.Keywords
This publication has 24 references indexed in Scilit:
- The Impact of a Prior Diagnosis of Barrett’s Esophagus on Esophageal Adenocarcinoma SurvivalAmerican Journal of Gastroenterology, 2017
- Systematic review with meta‐analysis: prevalent vs. incident oesophageal adenocarcinoma and high‐grade dysplasia in Barrett's oesophagusAlimentary Pharmacology & Therapeutics, 2016
- Metabolic syndrome in relation to Barretts esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research DatalinkCancer Epidemiology, 2016
- ACG Clinical Guideline: Diagnosis and Management of Barrett’s EsophagusAmerican Journal of Gastroenterology, 2016
- Metabolic Syndrome Increases Risk of Barrett Esophagus in the Absence of Gastroesophageal RefluxJournal of Clinical Gastroenterology, 2015
- Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control StudyPLOS Medicine, 2015
- Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesisNature Communications, 2014
- Association Between Markers of Obesity and Progression From Barrett's Esophagus to Esophageal AdenocarcinomaClinical Gastroenterology and Hepatology, 2013
- Trends in esophageal adenocarcinoma incidence and mortalityCancer, 2012
- Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic reviewGastroenterology, 2002